1. Home
  2. NEXT vs GENB Comparison

NEXT vs GENB Comparison

Compare NEXT & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NextDecade Corporation

NEXT

NextDecade Corporation

HOLD

Current Price

$8.31

Market Cap

1.5B

Sector

Energy

ML Signal

HOLD

GENB

Generate Biomedicines Inc. Common Stock

N/A

Current Price

$12.01

Market Cap

1.7B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
NEXT
GENB
Founded
2010
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Sector
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.7B
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
NEXT
GENB
Price
$8.31
$12.01
Analyst Decision
Hold
Strong Buy
Analyst Count
2
5
Target Price
$7.50
$25.00
AVG Volume (30 Days)
6.3M
437.9K
Earning Date
05-05-2026
05-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$45.45
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.75
$11.00
52 Week High
$12.12
$14.21

Technical Indicators

Market Signals
Indicator
NEXT
GENB
Relative Strength Index (RSI) 71.76 47.66
Support Level $8.09 $11.21
Resistance Level $9.08 $13.42
Average True Range (ATR) 0.68 1.16
MACD 0.07 0.07
Stochastic Oscillator 90.89 29.35

Price Performance

Historical Comparison
NEXT
GENB

About NEXT NextDecade Corporation

NextDecade Corp is a Houston-based energy company engaged in construction and development activities related to the liquefaction of natural gas, the sale of LNG, and the capture and storage of CO2 emissions. The group is constructing and developing a natural gas liquefaction and export facility located in the Rio Grande Valley near Brownsville, Texas (the Rio Grande LNG Facility). It also engaged in NEXT Carbon Solutions, advancing proprietary processes to lower the cost of utilizing carbon capture and storage (CCS) and help companies reduce their emissions and achieve their clean energy goals.

About GENB Generate Biomedicines Inc. Common Stock

Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.

Share on Social Networks: